Parallax Volatility Advisers’s Intellia Therapeutics NTLA Stock Holding History

Parallax Volatility Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-400	Closed	-$14.9K	–	2740
2023 Q1	$14.9K	Hold	400	–	–	﹤0.01%	2355
2022 Q4	$14K	Sell	400 -74,600	-99%	-$3.55M	﹤0.01%	2526
2022 Q3	$4.2M	Buy	75,000 +74,900	+74,900%	+$4.65M	0.01%	1095
2022 Q2	$5K	Buy	+100	New	+$5.08K	﹤0.01%	2726
2021 Q4	–	Sell	-27,600	Closed	-$3.7M	–	2183
2021 Q3	$3.7M	Buy	+27,600	New	+$4.18M	﹤0.01%	925
2020 Q4	–	Sell	-35,800	Closed	-$712K	–	3080
2020 Q3	$712K	Buy	+35,800	New	+$746K	﹤0.01%	2125
2018 Q3	–	Sell	-17,700	Closed	-$483K	–	3253
2018 Q2	$483K	Buy	+17,700	New	+$429K	﹤0.01%	1280

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's NTLA Position: Q4 2024 in Review

Parallax Volatility Advisers sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 35,994 shares — an estimated $740K sold.

Parallax Volatility Advisers first reported a position in NTLA in Q4 2017 and held it in 9 quarters. The position peaked at $1.56M in Q2 2022. 294 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

Parallax Volatility Advisers reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
Parallax Volatility Advisers sold 35,994 Intellia Therapeutics shares in Q4 2024, an estimated $740K.
Parallax Volatility Advisers first reported a position in Intellia Therapeutics in Q4 2017 and held it in 9 quarters.
Parallax Volatility Advisers's Intellia Therapeutics position peaked at $1.56M in Q2 2022.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Parallax Volatility Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.